Dte vltr dating
Late Friday, the company said it's in discussions with the underwriters of its initial public offering regarding the potential early release of about 18 million shares of its common stock from lock-up. The company said that during a review of strategic alternatives it discovered that a change in ownership took place in September 2003.
Volterra expects the lock-up restriction, which is currently scheduled to expire on Jan. As a result, about two-thirds of its net operating loss carryforwards will expire unused.
Isco also said it expects revenue of 0,000 for the fourth quarter, and that it has purchase orders worth more than .5 million scheduled for shipment in the first quarter.
Shares of Lazare Kaplan climbed nearly 5 percent after the diamond retailer reported an 11 times increase in its second-quarter earnings.
Sales jumped 38 percent in the latest three months to .9 million from .8 million in the same period a year earlier.
The company said the latest results include 8,000 in relocation and facility operation costs. shares rose more than 7 percent after the software company said it named Richard Tingle to its board, effective immediately.
SYS Technologies shares added nearly 5 percent after the company said it paid .6 million in cash and stock for privately held Antin Engineering of San Diego. 30, 2004 were million with a current annual run rate of million, SYS said. shares rose nearly 13 percent after the company said it expects third-quarter earnings "comfortably" above its previous forecast of 26 cents to 28 cents a share.
The company said its sales backlog was "reduced somewhat" in the quarter to about million as of Dec. shares gained more than 8 percent after the company said Friday that it has purchased the exclusive worldwide marketing and licensing rights for the XOXO fragrance brand from Victory International. The company recorded income from continuing operations of .8 million, or 17 cents a share, against the Thomson First Call-derived estimate for earnings of 14 cents a share.
Additionally, Torch has received a commitment for .9 million in new debtor-in-possession financing from Regions Bank and Export Development Canada. said the Food and Drug Administration has approved their drug Abraxane for injectable suspension in metastatic breast cancer. Its previous outlook was for earnings of .05 to .15 a share, while the Thomson First Call-derived estimate was for earnings of .07 a share.